These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 2163539

  • 1. Changes in locomotion and dopamine neurotransmission following amphetamine, haloperidol, and exposure to novel environmental stimuli.
    Bardo MT, Bowling SL, Pierce RC.
    Psychopharmacology (Berl); 1990; 101(3):338-43. PubMed ID: 2163539
    [Abstract] [Full Text] [Related]

  • 2. The effect of environmental enrichment on amphetamine-stimulated locomotor activity, dopamine synthesis and dopamine release.
    Bowling SL, Rowlett JK, Bardo MT.
    Neuropharmacology; 1993 Sep; 32(9):885-93. PubMed ID: 8232791
    [Abstract] [Full Text] [Related]

  • 3. Effects of d-amphetamine on dopaminergic neurotransmission; a comparison between the substantia nigra and the striatum.
    Elverfors A, Nissbrandt H.
    Neuropharmacology; 1992 Jul; 31(7):661-70. PubMed ID: 1328918
    [Abstract] [Full Text] [Related]

  • 4. The effects of GBR 12909, a dopamine re-uptake inhibitor, on monoaminergic neurotransmission in rat striatum, limbic forebrain, cortical hemispheres and substantia nigra.
    Nissbrandt H, Engberg G, Pileblad E.
    Naunyn Schmiedebergs Arch Pharmacol; 1991 Jul; 344(1):16-28. PubMed ID: 1663587
    [Abstract] [Full Text] [Related]

  • 5. Differential effects of d-amphetamine, beta-phenylethylamine, cocaine and methylphenidate on the rate of dopamine synthesis in terminals of nigrostriatal and mesolimbic neurons and on the efflux of dopamine metabolites into cerebroventricular perfusates of rats.
    Nielsen JA, Chapin DS, Moore KE.
    Life Sci; 1983 Nov 07; 33(19):1899-907. PubMed ID: 6645784
    [Abstract] [Full Text] [Related]

  • 6. Interrelationships between plasma homovanillic acid and indices of dopamine turnover in multiple brain areas during haloperidol and saline administration.
    Csernansky JG, Barnes DE, Bellows EP, Lombrozo L.
    Life Sci; 1990 Nov 07; 46(10):707-13. PubMed ID: 2314192
    [Abstract] [Full Text] [Related]

  • 7. The response of non-dopamine neurons in substantia nigra and ventral tegmental area to amphetamine and apomorphine during hypermotility: the striatal influence.
    Olds ME.
    Brain Res; 1988 Jun 14; 452(1-2):237-54. PubMed ID: 3401732
    [Abstract] [Full Text] [Related]

  • 8. In vivo neurochemical and behavioural effects of intracerebrally administered neurotensin and D-Trp11-neurotensin on mesolimbic and nigrostriatal dopaminergic function in the rat.
    Ford AP, Marsden CA.
    Brain Res; 1990 Nov 26; 534(1-2):243-50. PubMed ID: 2073584
    [Abstract] [Full Text] [Related]

  • 9. The effect of chronic atypical antipsychotic drugs and haloperidol on amphetamine-induced dopamine release in vivo.
    Ichikawa J, Meltzer HY.
    Brain Res; 1992 Mar 06; 574(1-2):98-104. PubMed ID: 1379112
    [Abstract] [Full Text] [Related]

  • 10. Sensitization versus tolerance to the dopamine turnover-elevating effects of haloperidol: the effect of regular/intermittent dosing.
    Csernansky JG, Bellows EP, Barnes DE, Lombrozo L.
    Psychopharmacology (Berl); 1990 Mar 06; 101(4):519-24. PubMed ID: 2388975
    [Abstract] [Full Text] [Related]

  • 11. Neuroleptic-like disruption of the conditioned avoidance response requires destruction of both the mesolimbic and nigrostriatal dopamine systems.
    Koob GF, Simon H, Herman JP, Le Moal M.
    Brain Res; 1984 Jun 15; 303(2):319-29. PubMed ID: 6430466
    [Abstract] [Full Text] [Related]

  • 12. d-Amphetamine and gamma-butyrolactone alteration of dopamine synthesis in the terminals of nigrostriatal and mesolimbic neurons. Possible role of various autoreceptor sensitivities.
    Demarest KT, Lawson-Wendling KL, Moore KE.
    Biochem Pharmacol; 1983 Feb 15; 32(4):691-7. PubMed ID: 6403019
    [No Abstract] [Full Text] [Related]

  • 13. Environmental enrichment attenuates locomotor sensitization, but not in vitro dopamine release, induced by amphetamine.
    Bardo MT, Bowling SL, Rowlett JK, Manderscheid P, Buxton ST, Dwoskin LP.
    Pharmacol Biochem Behav; 1995 Feb 15; 51(2-3):397-405. PubMed ID: 7667360
    [Abstract] [Full Text] [Related]

  • 14. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways.
    Gobert A, Rivet JM, Audinot V, Cistarelli L, Spedding M, Vian J, Peglion JL, Millan MJ.
    J Pharmacol Exp Ther; 1995 Nov 15; 275(2):899-913. PubMed ID: 7473181
    [Abstract] [Full Text] [Related]

  • 15. Mesolimbic dopamine and early post-6-OHDA lesion enhanced responses to d-amphetamine.
    Lynch MR, Carey RJ.
    Pharmacol Biochem Behav; 1989 Feb 15; 32(2):577-80. PubMed ID: 2498910
    [Abstract] [Full Text] [Related]

  • 16. Further proof that (-)deprenyl fails to facilitate mesolimbic dopaminergic activity.
    Timár J, Gyarmati Z, Tekes K, Härsing GL, Knoll J.
    Pharmacol Biochem Behav; 1993 Nov 15; 46(3):709-14. PubMed ID: 8278449
    [Abstract] [Full Text] [Related]

  • 17. Hyperactivity and hypoactivity produced by lesions to the mesolimbic dopamine system.
    Koob GF, Stinus L, Le Moal M.
    Behav Brain Res; 1981 Nov 15; 3(3):341-59. PubMed ID: 6796098
    [Abstract] [Full Text] [Related]

  • 18. Effects of acute GR38032F (odansetron), a 5-HT3 receptor antagonist, on dopamine and serotonin metabolism in mesolimbic and nigrostriatal dopaminergic neurons.
    Koulu M, Sjöholm B, Lappalainen J, Virtanen R.
    Eur J Pharmacol; 1989 Oct 10; 169(2-3):321-4. PubMed ID: 2530097
    [Abstract] [Full Text] [Related]

  • 19. Dopamine characteristics in different rat genotypes: the relation to absence epilepsy.
    de Bruin NM, van Luijtelaar EL, Jansen SJ, Cools AR, Ellenbroek BA.
    Neurosci Res; 2000 Oct 10; 38(2):165-73. PubMed ID: 11000443
    [Abstract] [Full Text] [Related]

  • 20. Differential action of bromocriptine on nigrostriatal versus mesolimbic dopaminergic neurons.
    Barton AC, Moore KE, Demarest KT.
    J Neural Transm; 1987 Oct 10; 68(1-2):25-39. PubMed ID: 2879883
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.